Spotlight Stories

  1. I-MAK's Quest To Trim The Biopharmaceutical Patent Thicket 7/3/2023

    I-MAK, a nonprofit focused on reforming the drug patent system, is bringing patients into the patent system to advocate against abuses that keep affordable drugs out of reach.

  2. Civica Takes On Insulin Market, Opens Manufacturing Facility 7/3/2023

    With a new manufacturing plant opening in Virgina, Civica is poised to move into new product areas, including affordable insulin.

  3. Ways To Face New Bio Funding & Banking Risks 7/3/2023

    Funding bio startups has never been easy, but no doubt it just got harder. We wanted to find at least one company to talk about how it is handling the damage and aftermath of recent bank closures and other cash crunches, and we actually found two.

  4. From Biggest Pharma To Rare Disease Start-Up 6/1/2023

    Martin Mackay’s journey from Pfizer executive to founding and leading a rare disease biotech is a reflection of the industry’s evolution from a small molecule powerhouse to multimodal biotech. 

  5. Leading Aulos Bioscience's “Triumvirate” Model 6/1/2023

    Aulos Bioscience hopes to leverage its unique business model, engineered by a VC firm and an Israeli biotech, to develop better treatments for solid tumors.

  6. A Quick Transition To Late-Stage Clinical Trials 6/1/2023

    “Moving into Phase 3 not only expands the resources you need internally, but some things require a much larger amount of capital, and often a public listing so you can raise larger amounts of money,” says Eric Dobmeier, president and CEO, Chinook Therapeutics.

  7. Fortress Biotech's Network Flex Business Model 5/1/2023

    Fortress Biotech CEO Lindsay Rosenwald talks up Fortress Biotech’s business model, which leverages partner companies to develop promising but underexposed drug candidates.

  8. The Skin Is The Game: New Ways To Play In Dermatology 5/1/2023

    As the established indications in dermatology become saturated with competing products, a variety of companies, from start-ups to oncology players, are finding opportunities in underserved indications and reformulated drugs.

  9. Building It All In-House 5/1/2023

    Kriya’s firm commitment to build or bring all key functions in house may be unusual for such a young enterprise, but it has been consistent from the beginning.

  10. Hitting The Ground Running In Oncology 4/3/2023

    David Lee, CEO at Servier Pharmaceuticals, talks about how he set up the French company’s U.S. division, and his goal of reaching $2 billion in annual oncology product revenue.